Pharmaceutical residues in the drinking water supply: Modeling residue concentrations in surface waters of drugs prescribed in the United States

Puerto Rico Health Sciences Journal

Volumn 27, Issue 3, 2008, Pages 236-240

  Guerrero Preston, Rafael ^a,b,d   Brandt Rauf, Paul ^a,c  

^a Mailman School of Public Health   (United States)

^b UNIVERSITY OF PUERTO RICO   (Puerto Rico)

^c Fu Foundation School of Engineering and Applied Science   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Drinking water source quality; Pharmaceutical residues in drinking water; Public health engineering

Indexed keywords

DRUG RESIDUE; PRESCRIPTION DRUG; UNCLASSIFIED DRUG;

ARTICLE; UNITED STATES; WATER POLLUTANT; WATER SUPPLY;

DRUG RESIDUES; PRESCRIPTION DRUGS; UNITED STATES; WATER POLLUTANTS; WATER SUPPLY;

EID: 58149129997     PISSN: 07380658     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Ternes TA, et al. Behavior and occurrence of estrogens in municipal sewage treatment plants-I. Investigations in Germany, Canada and Brazil. Sci Total Environ 1999;225:81-90.
2. Hirsch R, et al. Occurrence of antibiotics in the aquatic environment. Sci Total Environ 1999;225:109-118.
3. Sacher F, et al. Pharmaceuticals in groundwaters analytical methods and results of a monitoring program in Baden-Wurttemberg, Germany. J Chromatogr A2001;938:199-210.
4. Pedrouzo M, et al. Pharmaceutical determination in surface and wastewaters using high-performance liquid chromatography-(electrospray)-mass spectrometry. J Sep Sci 2007;30:297-303.
5. Gaylor DW, PM Bolger, BASchwetz. U.S. Food and Drug Administration perspective of the inclusion of effects of low-level exposures in safety and risk assessment. Environ Health Perspect 1998;106(Suppl 1):391-394.
6. Pomati F, et al. Effects of a complex mixture of therapeutic drugs at environmental levels on human embryonic cells. Environ Sci Technol 2006;40:2442-2447.
7. Metcalfe CD, et al. Distribution of acidic and neutral drugs in surface waters near sewage treatment plants in the lower Great Lakes, Canada. Environ Toxicol Chem 2003;22:2881-2889.
8. Brooks BW, et al. Aquatic ecotoxicology of fluoxetine. Toxicol Lett 2003;142:169-183.
9. Knacker T, et al. The EU-project ERAPharm. Incentives for the further development of guidance documents? Environ Sci Pollut Res Int 2005;12:62-65.
10. USGS Water Use 2000. 2006, United States Geological Service.
11. Barnes KK, KD, Meyer MT, Thurman EM, Furlong ET, Zaugg SD, Barber LB. Water-Quality Data for Pharmaceuticals, Hormones, and Other Organic Wastewater Contaminants in U.S. Streams, 1999-2000. USGS Open-File Report 2002.
12. Jones OA, N Voulvoulis, JN Lester. Aquatic environmental assessment of the top 25 English prescription pharmaceuticals. Water Res 2002;36:5013-5022.
13. Stuer-Lauridsen F, et al. Environmental risk assessment of human pharmaceuticals in Denmark after normal therapeutic use. Chemosphere 2000;40:783-793.
14. Raftelis. The 2002 Water and Wastewater Survey. Raftelis Financial Consulting: Charlotte, NC. 2004.
15. FDA, Environmental assessment of human drugs and biologics applications. 1998, US Food and Drug Administration.
16. Ritter L, et al. Sources, pathways, and relative risks of contaminants in surface water and groundwater: a perspective prepared for the Walkerton inquiry. J Toxicol Environ Health A 2002;65:1-142.
17. Ferrari B, et al. Environmental risk assessment of six human pharmaceuticals: are the current environmental risk assessment procedures sufficient for the protection of the aquatic environment? Environ Toxicol Chem 2004;23:1344-1354.
18. Stackelberg PE, et al. Persistence of pharmaceutical compounds and other organic wastewater contaminants in a conventional drinking-water-treatment plant. Sci Total Environ 2004;329:99-113.